RESULTS
T2D, T1D, DKA, diabetes type, diabetes
EVENTS, EVENT, DIABETES
A total of 77 participants were enrolled in the ANSHIN study, and 67 participants continued through phase two (Table Participant characteristics.18 Participants in phase one and 15 participants in phase two had missing diabetes duration.Mean HbA1c was reduced by 1.1 percentage points (Comparison of baseline and end of phase one glycaemic outcomes stratified by participants with T1D or T2D.


Scatter plot for HbA1c (%) at end of phase one versus baseline.Older participants ≥65 years also achieved significant HbA1c reductions after the first CGM intervention phase. Mean HbA1c for older adults decreased to 8.2% (1.4%) after non‐adjunctive CGM use with a mean reduction of 1.0 percentage points (Comparison of baseline and end of phase one glycaemic outcomes for participants ≥65 years.

Glycaemic outcomes from end of phase one to end of phase two stratified by diabetes type and age.Between baseline and the end of the first phase, TIR improved significantly. CGM outcomes for those with T1D or T2D are summarized in Table There were three SH events from three participants during the 20‐day run‐in period, four SH events from four participants during the phase one CGM intervention period, and no SH events during phase two. SH events were unrelated to CGM use and were resolved by assisted intervention or, in one milder case, self‐treatment. The SH incidence rate was 67.3 events per 100 person‐years at baseline and 17.8 events per 100 person‐years during phase one, a 74% decrease. There were no DKA events during 20‐day run‐in period and two DKA events from one participant with T1D during phase one that were unrelated to CGM use. There was one additional DKA event from one participant with T2D during phase two that was unrelated to CGM use.While this study did not aim to assess CGM accuracy, we report that the Dexcom G6 systems placed on the posterior arm tended to produce lower glucose values than systems placed on the abdomen. Arm‐derived glucose values were lower with median (IQR) difference of −0.3 (−1.1, +0.4) mmoL/L.